Shares in Intercell hit an all-time high during early trading Monday on news that it had entered a broadly based alliance with Novartis AG, with a guaranteed cash element of €270 million (US$366.7 million), comprising an up-front, option and license payment of €120 million and a stock purchase worth €150 million. It could earn several hundred million more, through milestones from or profit shares in multiple development programs. (BioWorld International)
Probiodrug AG has acquired fellow German firm Ingenium Pharmaceuticals AG in a stock-based deal and has closed a €20.6 million (US$27.7 million) venture capital round at the same time, to fund both an in-house drug development program in Alzheimer's disease and a newly acquired program in inflammation. (BioWorld International)
Probiodrug AG has acquired fellow German firm Ingenium Pharmaceuticals AG in a stock-based deal and has closed a €20.6 million (US$27.7 million) venture capital round at the same time, to fund both an in-house drug development program in Alzheimer's disease and a newly acquired program in inflammation. (BioWorld International)
Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International)
